Evidence map›Paper›PMID 28986775›Full record

ArticleMedical oncology (Northwood, London, England)2017

Timeline metastatic progression: in the wake of the « seed and soil » theory.

Aymeric Amelot, Louis-Marie Terrier, Jean-Jacques Mazeron, Charles-Ambroise Valery, Philippe Cornu, Alexandre Carpentier, Marc Leveque

Abstract read
PubMed Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Can anticancer chemotherapy promote the progression of brain metastases?Medical oncology (Northwood, London, England) · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Aymeric AmelotDepartment of Neurosurgery, Groupe Hospitalier Pitié-Salpétrière, APHP, Paris, France. aymmed@hotmail.fr.ORCID http://orcid.org/0000-0003-3659-291X
Louis-Marie TerrierDepartment of Neurosurgery, Hopital Bretonneau, Tours, France.
Jean-Jacques MazeronUniversité Paris VI - Pierre et Marie Curie, Paris, France.
Charles-Ambroise ValeryDepartment of Neurosurgery, Groupe Hospitalier Pitié-Salpétrière, APHP, Paris, France.
Philippe CornuDepartment of Neurosurgery, Groupe Hospitalier Pitié-Salpétrière, APHP, Paris, France.
Alexandre CarpentierDepartment of Neurosurgery, Groupe Hospitalier Pitié-Salpétrière, APHP, Paris, France.
Marc LevequeDepartment of Neurosurgery, Groupe Hospitalier Pitié-Salpétrière, APHP, Paris, France.
Université Paris Cité · FRCentre Hospitalier Universitaire de Tours · FRSorbonne Université · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Little is known about the natural history of cancer and its evolution to metastasis. Paget was the first to postulate the important role played by microenvironment in metastasis progression. Since, the concept of his "seed and soil" theory has been supported and confirmed. Understanding the chronology and natural course that underlie metastasis is mandatory to deepen this concept and to progress in the development of novel therapeutic strategies. A total of 413 patients who underwent treatment for brain metastasis (2013-2016) were included. The identification of previous and newly diagnosed metastasis was made during the clinical and imaging follow-up. We identified 910 metastases in our series. The 2-, 5-, and 10-year survival estimates were 80% (SD 2), 59.1% (3), and 36% (4), respectively. The median time for first metastasis, referred as metastasis-free survival (MFS) was 15.2 months (SD 1.47). MFS were determined for each metastasis location and were as follows: 7.2 months (SD 8.0) for bone, adrenal 8.4 months (SD 9.4) for adrenal, 13.2 months (SD 1.7) for brain, 14.6 months (SD 5.4) for liver, 25.7 months (SD 11.7) for pleura, 27.7 months (SD 15.9) for peritoneum, 29.8 months (SD 7.2) for spine, 30.2 months (SD 5.2) for lungs, and 54.2 months (SD 12.4) for skin (p < 0.009 log rank). We identified a metastatic timeline process for breast cancer (p < 0.0001 log rank (Mantel-Cox)) and furthermore according to breast subtype cancer (p < 0.0001). We suggest that in addition to Paget's theory, a timeline and a natural history of metastasis exist in patients with cancer. We suppose that some, but not all, primary cancers follow chronological and scheduled metastatic processes to invade organs.

Indexed as

AdolescentAdultAgedAged, 80 and overBrain NeoplasmsBreast NeoplasmsCarcinoma, Renal CellFemaleHumansKidney NeoplasmsLung NeoplasmsMaleMelanomaMiddle AgedMutationProto-Oncogene Proteins B-rafBRAF protein, humanProto-Oncogene Proteins B-rafChronologyMetastasisMetastatic progressionSurvivalTimeline

Identifiers

PMID28986775
OpenAlexW2762689118

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.